The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Review initially finds dolutegravir has no links to birth defects then revises its findings to report a ‘slightly higher’ – but minimal – incidence after two cases emerge
National data from five Southern African countries suggests nearly 89% of adults on HIV treatment are virally suppressed – but gaps remain.
Malawians in some rural areas face travel times to HIV clinics that are almost double others’ journeys.
Rates of viral suppression among men significantly increase – and approach that of women – when services are provided in the community instead of in-clinic.
Long-acting, injectable cabotegravir is as effective as daily PrEP pills at preventing HIV among cisgender men and transgender women who have sex with men.
People on integrase inhibitors found to gain more weight on average than those on other treatment regimens
Despite the country’s successful treatment programme, modelling suggests the rate of new infections is likely to rise – unless prevention is strengthened and groups such as migrants included.
South African trial finds 90% of people receiving rapid viral load testing were virally suppressed and in care after 12 months, compared to 76% who waited for tests.
HIV incidence more than halved among people from fishing communities in Lake Victoria, Uganda, after rapid expansion of HIV services.
Routine point‐of‐care viral load monitoring achieves high testing coverage rates and same-day delivery of results in decentralised clinics.